


**Amendments to the Claims:**

This listing of Claim will replace all prior versions, and listings, of claims in the application.

**Listing of claims:**

Claims 1-45 (cancelled).

46. (New) A compound having the Formula IIa,



or a pharmaceutically acceptable salt thereof or an individual diastereomer thereof, wherein:

X and Z are C;

R<sup>1</sup> is selected from: -C<sub>1-6</sub>alkyl unsubstituted or substituted with 1-6 substituents independently selected from halo, hydroxy, -O-C<sub>1-3</sub>alkyl and trifluoromethyl; and phenyl unsubstituted or substituted with 1-3 substituents independently selected from halo, hydroxyl, C<sub>1-3</sub>alkyl, C<sub>1-3</sub>alkoxy and trifluoromethyl;

R<sup>2</sup> and R<sup>3</sup> are independently selected from: hydrogen, fluoro, chloro, and C<sub>1-3</sub>alkyl unsubstituted or substituted with 1-3 fluoro;

R<sup>5</sup> is selected from fluoro, chloro, and -C<sub>1-6</sub>alkyl unsubstituted or substituted with 1-6 substituents selected from fluoro;

R<sup>7</sup> is fluorophenyl;

R<sup>8</sup> is hydrogen;

or R<sup>7</sup> and R<sup>8</sup> join to form a 1H-indene ring, which is optionally substituted with 1-5 substituents independently selected from halo, trifluoromethyl, and C<sub>1-3</sub>alkyl;

A is selected from -O- and -N(R<sup>20</sup>)-;

R<sup>9</sup> and R<sup>10</sup> are independently selected from: hydrogen and C<sub>1-6</sub>alkyl;

R<sup>19</sup> is selected from: hydrogen and C<sub>1-6</sub> alkyl; and

R<sup>20</sup> is selected from: hydrogen, C<sub>1-6</sub> alkyl, C(=O)CH<sub>3</sub>, and BOC.

47. (New) The compound of claim 46, wherein

R<sup>1</sup> is selected from: -C<sub>1-6</sub>alkyl unsubstituted or substituted with 1-6 substituents independently selected from halo; and phenyl unsubstituted or substituted with 1-3 substituents independently selected from halo, C<sub>1-3</sub>alkyl, and trifluoromethyl.

48. (New) The compound of claim 46, wherein R<sup>2</sup> is H.


49. (New) The compound of claim 46, wherein R<sup>3</sup> is selected from: trifluoromethyl, chloro, and fluoro.

50. (New) The compound of claim 46, wherein R<sup>5</sup> is selected from hydrogen, trifluoromethyl, chloro and fluoro.

51. (New) The compound of claim 46, where R<sup>7</sup> and R<sup>8</sup> join to form a 1H-indene ring, wherein said ring is unsubstituted.

52. (New) The compound of Claim 46, wherein R<sup>19</sup> and R<sup>2</sup> are H.

53. (New) A compound selected from the group consisting of:



or a pharmaceutically acceptable salt thereof, or individual diastereomer thereof.

54. (New) A pharmaceutical composition which comprises an inert carrier and the compound of Claim 46.

55. (New) A method for modulation of chemokine receptor activity in a mammal which comprises the administration of an effective amount of the compound of Claim 46.